Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection Handb Clin Neurol. 2018;152:177–86.

Article  PubMed  Google Scholar 

Kimani SM, Painschab MS, Horner MJ, Muchengeti M, Fedoriw Y, Shiels MS, et al. Epidemiology of haematological malignancies in people living with HIV. Lancet HIV. 2020;7(9):e641–51.

Article  PubMed  PubMed Central  Google Scholar 

Ding X, Liang T, Liang B, Gao H, Wang J, Liu H, et al. Diagnostic value of EBV-DNA in CSF for PCNSL in AIDS patients with focal brain lesions: a meta-analysis of diagnostic test. Med (Baltim). 2022;101(48):e31793.

Article  CAS  Google Scholar 

Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, et al. A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem. 2022;3(3):734–8.

Article  PubMed  PubMed Central  Google Scholar 

Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011;101(2):257–65.

Article  PubMed  Google Scholar 

Moulignier A, Lamirel C, Picard H, Lebrette MG, Amiel C, Hamidi M, et al. Long-term AIDS-related PCNSL outcomes with HD-MTX and combinedantiretroviral therapy. Neurology. 2017;89(8):796–804.

Article  CAS  PubMed  Google Scholar 

Lurain K, Uldrick TS, Ramaswami R, Polizzotto MN, Goncalves PH, Widell A, et al. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 2020;136(19):2229–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schaff LR, Grommes C. Update on Novel therapeutics for primary CNS lymphoma. Cancers (Basel). 2021;13(21):5372.

Article  CAS  PubMed  Google Scholar 

Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving treatments for primary Central Nervous System Lymphoma. Am Soc Clin Oncol Educ Book. 2019;39:454–66.

Article  PubMed  Google Scholar 

Verdu-Bou M, Tapia G, Hernandez-Rodriguez A, Navarro JT. Clinical and therapeutic implications of Epstein-Barr Virus in HIV-Related Lymphomas. Cancers (Basel). 2021;13(21):5534.

Article  CAS  PubMed  Google Scholar 

González-Aguilar A, Soto-Hernández JL. The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr Opin Oncol. 2011;23(6):648–53.

Article  PubMed  Google Scholar 

Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ambady P, Szidonya L, Firkins J, James J, Johansson K, White T, et al. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma. 2019;60(2):515–8.

Article  CAS  PubMed  Google Scholar 

Chen FL, Pang DW, Guo HG, Ou QX, Wu X, Jiang XM. Clinical outcomes of newly diagnosed primary CNS lymphoma lymphoma treated with ibrutinib-based combination therapy: a real-world experience of off-label ibrutinib use. Cancer Med. 2020;9(22):8676–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang XX, Gao Y, Yu SS, Bai B, Ou QX, Zhu LQ, et al. Preliminary results of a phase II study of methotrexate in combination with ibrutinib and temozolomide (MIT) in newly diagnosed primary CNS lymphoma. Blood. 2021;138(S1):2481–3.

Article  Google Scholar 

Yang C, Cui Y, Ren X, Li M, Yu K, Shen S, et al. Orelabrutinib combined with lenalidomide and immunochemotherapy for Relapsed/Refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol. 2022;12:901797.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu JJ, Wang WH, Dong M, Ma SS, Zhang XD, Zhu LN Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: A retrospective study. Invest New Drugs. 2022;40(3):650–9.

Tsuyuki Y, Ishikawa E, Kohno K, Shimada K, Ohka F, Suzuki Y, et al. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-celllymphoma of the central nervous system. Neuropathology. 2021;41(2):99–108.

Monabati A, Nematollahi P, Dehghanian A, Safaei A, Sadeghipour A, Movahedinia S, et al. Immune Checkpoint Molecules in primary diffuse large B-Cell lymphoma of the Central Nervous System. Basic Clin Neurosci. 2020;11(4):491–8.

Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M et al. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: the role of programmed cell death 1 and programmed cell death ligand 1.Neuropathology.2018;38(2):125–34.

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib mono-therapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the french oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–30.

Article  CAS  PubMed  Google Scholar 

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton Tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the french oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–30.

Article  CAS  PubMed  Google Scholar